Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 11/20 | 0.69 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.59 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.59 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.59 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.59 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.59 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.59 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.59 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.59 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.59 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.59 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.59 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.59 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.59 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.59 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.59 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.59 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.59 |
| ▸ | PSMC2 | P35998 | 1/20 | 0.59 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11396664 | 0.80 | PSMB8 (0.69) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1780955 | 0.80 | PSMB8 (0.69) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL4177855 | 0.80 | PSMB8 (0.69) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1783240 | 0.80 | PSMB8 (0.63) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL4113266 | 0.79 | PSMB8 (0.59) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1781945 | 0.79 | PSMB8 (0.68) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1781069 | 0.78 | PSMB8 (1.00) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1780464 | 0.76 | PSMB8 (0.63) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL1504647 | 0.75 | PSMB8 (0.61) | PSMB8PSMB11PSMD11PSMD12PSMD14 | |
| SCHEMBL4114062 | 0.74 | PSMB8 (0.53) | PSMB8PSMB11PSMD11PSMD12PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-05-19 | — | — | US | claimed |
| WO-2009026579-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009026579-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | CORNELL RESEARCH FOUNDATION, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-0064582-A1 | Starting compounds for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-11-17 | — | — | EP | disclosed |
| US-4261728-A | PREEMERGENT ACTIVITY | MONSANTO COMPANY (US) | 1981-04-14 | — | — | US | disclosed |
| US-4187099-A | 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118274-A1 | PROTEASOME INHIBITORS AND THEIR USE IN TREATING PATHOGEN INFECTION AND CANCER | PSMB1, PSME1, PSMB2 | PSMB8 22/4885PSMB11 7/4885PSMD11 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.